However, we show that the FGF14 GAA≥250 has an impact on the functional status of MSA patients, leading to a significantly higher proportion of cases presenting with falls in the first year from onset in the FGF14 GAA-positive MSA patients compared with FGF14 GAA-negative MSA cases (P = 0.03), a significantly reduced time to falls (P = 0.03) and shorter time to wheelchair use (P = 0.02). This evidence concerns the gene FGF14 and multiple system atrophy.